Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis
LOS ANGELES -- Citing another failed clinical trial in women of the use of Gilead Sciences' AIDS drug Truvada as a form of Pre-exposure Prophylaxis
(PrEP) to prevent HIV infection, AIDS Healthcare Foundation (AHF), the nation's largest HIV/AIDS nonprofit medical provider, today urged the Food and Drug Administration (FDA) to remove this indication for use by women citing insufficient data demonstrating the drug's safety and efficacy.
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis
efficacy in men who have sex with men.
To do this, the individual must be tested and prove to be HIV negative prior to starting on pre-exposure prophylaxis
The United States Food and Drug Administration (FDA) has registered Truvada for pre-exposure prophylaxis
for men and women.
Other important interventions include medical male circumcision, which offers a highly effective and durable way to protect heterosexual men from HIV infection; and potentially, pre-exposure prophylaxis
with antiretroviral medications, which have shown promise in reducing an individual's risk of acquiring HIV infection.
The guidance is based on clinical trials indicating that HIV-negative people taking a daily dose of oral antiretroviral medication, known as pre-exposure prophylaxis
(PrEP), to reduce the risk of infection, is both safe for people to use and effective in preventing HIV.
The study had enrolled 5,029 sexually active, HIV-negative women to test the daily use of two different oral antiretrovirals as pre-exposure prophylaxis
(PREP): tenofovir and a combination tablet containing emtricitabine and tenofovir (known by the trademark Truvada), and a vaginal gel containing 1% tenofovir.
New HIV prevention options such as Treatment for Prevention, CAPRISA gel - a female controlled microbicide, and iPreX - a pre-exposure prophylaxis
- have emerged adding hope to people who want to protect themselves and their loved ones from the virus.
Over the next 5-10 years, it is likely that the UK will see the development and implementation of guidelines for the provision of pre-exposure prophylaxis
(PrEP) to those people who are at significant risk of acquiring HIV infection.
Initial commitment to pre-exposure prophylaxis
and circumcision for HIV prevention amongst Indian truck drivers.
Additional emerging technologies include other STD vaccines, (9) microbicides (10) and pre-exposure prophylaxis
for HIV prevention (PREP).